QYQing Yi

Qing Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qing Yi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Bart Barlogie

    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, and

    1 shared publication
  • Bart Barlogie

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    1 shared publication
  • Joshua Epstein

    Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR 72205, USA

    1 shared publication
  • Nikhil Munshi

    Central Arkansas Veterans Medical Center, Little Rock, AR, USA

    1 shared publication
  • Raman Desikan

    Central Arkansas Veterans Medical Center, Little Rock, AR, USA

    1 shared publication
  • Rui Min

    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    1 shared publication

Latest Publications

  • Immunotherapy in multiple myeloma: current strategies and future prospects

    by Qing Yi

    Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy supported by autologous transplantations, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for post-transplantation immunomodulation would be desirable for eradication of remaining tumor cells. Toward this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been exploited. Idiotype protein, secreted by myeloma cells, has been the main target for immunotherapy as it is the best-defined, tumor-specific antigen. The focus of this review article is the use of idiotype as a form of protein antigen to immunize patients, to load dendritic cells, or as part of DNA vaccines. Various strategies of immunotherapy and the outcome of clinical trials are also discussed.


  • Dendritic Cell-based Immunotherapy in Multiple Myeloma

    by Qing Yi

    Most patients with multiple myeloma (MM) cannot be cured with currently available therapies. Although complete remission could be achieved in about 50% of newly diagnosed patients with high-dose chemotherapy and tandem transplantation, relapses of the underlying disease occur frequently. To realize long-term disease-free survival, it will be necessary to develop complementary therapies that are non-cross-resistant with chemotherapy. To this end, immunotherapy aimed at inducing or enhancing tumor-specific immunity that may control or eradicate remaining tumor cells may be an appealing method. Dendritic cells (DCs) are professional antigen-presenting cells and considered the best natural adjuvants for immunotherapy in malignancies. Vaccination with tumor antigen-pulsed DCs has been shown to be protective and therapeutic in animal tumor models, and induced a strong tumor-specific immunity and durable tumor regression in human solid tumors and B-cell lymphoma. As a result, clinical trials in various human malignancies have been initiated. This review will focus on DC-based immunotherapy in MM. I will discuss myeloma antigens and antigen-specific immune responses, the capacity of DCs to present myeloma antigens and induce cytotoxic T-cell responses, and clinical experience of DC vaccination in myeloma patients.


  • β2-microglobulin as a negative growth regulator of myeloma cells

    by Rui Min, Zhongkui Li, Joshua Epstein, Bart Barlogie, Qing Yi

    High beta(2)-microglobulin (beta(2)m) levels in myeloma correlate with poor prognosis. We hypothesized that beta(2)m may affect myeloma cell growth and survival. In this study, we examined the in vitro effects of beta(2)m on myeloma cells. Primary myeloma cells freshly isolated from patients and myeloma cell lines were used, cultured in the presence of beta(2)m, and monitored for growth and survival. Beta(2)m suppressed the growth of primary tumour cells and myeloma cell lines (ARK-RS, ARP-1, RPMI-8226, U266, ARH-77 and IM-9). High concentrations of beta(2)m induced apoptosis and cell cycle arrest. Beta(2)m-induced apoptosis was dependent on activation of a caspase cascade, inhibited by interleukin 6, and did not involve the surface death receptors, as receptor-neutralizing antibodies had no inhibitory effect. Beta(2)m-induced growth arrest was associated with downregulation of cyclins A and D2. Surprisingly, anti-beta(2)m antibodies did not block the effect of beta(2)m but were synergistic with beta(2)m, resulting in 90% growth inhibition and 70% apoptosis of myeloma cells. Whereas beta(2)m treatment resulted in slight upregulation of surface beta(2)m and major histocompatibility complex class I alpha-chain expression, treatment of myeloma cells with anti-beta(2)m antibodies alone or with beta(2)m resulted in significant downregulation of surface beta(2)m and class I molecules, suggesting that class I molecules may be involved in signal transduction. Our data demonstrate that beta(2)m plays an important role in regulating the growth and survival of myeloma cells in vitro and warrants further investigation to delineate the mechanisms of beta(2)m and anti-beta(2)m antibody-induced growth regulation of myeloma cells.


  • Open Access

    Optimizing dendritic cell‐based immunotherapy in multiple myeloma

    by Qing Yi, Raman Desikan, Bart Barlogie, Nikhil Munshi

    Summary. Vaccination with idiotype protein‐pulsed dendritic cells (DCs) has been explored in multiple myeloma and the results have been disappointing. These studies used immature DCs, which are less potent at activating T cells and could differentiate to macrophages once the cytokines were withdrawn. After intravenous administration, DCs accumulate in the lungs and liver for up to 48 h, thus reducing their potential to migrate to lymphoid organs and interact with T cells. To improve the efficacy of DC vaccination in myeloma, we investigated the use of idiotype‐pulsed mature DCs administered subcutaneously. Five patients (three IgG and two IgA myeloma) with stable partial remission following high‐dose chemotherapy were enrolled. DC vaccines were administered three times at 2‐week intervals at least 4 months post transplantation. Idiotype‐specific T‐cell responses, detected using enzyme‐linked immunospot (ELISPOT) (four patients) and proliferation (two patients) assays, were elicited in four and anti‐idiotypic B‐cell responses in all five patients. The cytokine‐secretion profile of activated T cells demonstrated a type‐1 response. A 50% reduction in serum M‐component was observed in one immunologically responding patient that persisted for 6 months and stable disease (for 6 months) resulted in the other three patients. The remaining patient without an immune response to the vaccination relapsed. No major side‐effects were noted. Thus, subcutaneous administration of idiotype‐pulsed mature DCs induced idiotype‐specific T‐ and B‐cell responses. Current efforts are geared towards optimizing the conditions of DC generation and administration, and the development of in vitro assays to monitor the cytotoxicity of the T cells.